Crystalys Therapeutics

Crystalys Therapeutics is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of gout. Headquartered in San Diego, California, and co-founded by Catalys Pacific and Novo Holdings, Crystalys has assembled a world-class team with deep expertise in gout drug development, committed to providing more effective options for patients with gout. The company’s lead candidate, dotinurad, is a next-generation once-daily oral URAT1 inhibitor currently in clinical development as a second-line therapy aimed at reducing uric acid, gout flares, and tophi. Dotinurad was invented by Fuji Yakuhin and has received regulatory approval in Japan, China, the Philippines, and Thailand. Dotinurad demonstrates best-in-class potential in terms of safety and efficacy, supported by clinical data from multiple Asian markets. Crystalys is advancing dotinurad through global Phase 3 trials to secure regulatory approvals and commercial launch.